<p>在最新的季度中，5 位分析師對 Harmony Biosciences Hldgs（納斯達克：HRMY）提供了評級，展現出看漲和看跌的不同觀點。</p>
<p>以下表格總結了他們最近的評級，提供了過去 30 天情緒變化的概覽，並與前幾個月進行了比較。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析師分析的 12 個月價格目標提供了見解，平均目標為 46.8 美元，最高預估為 55.00 美元，最低預估為 42.00 美元。當前平均目標較之前的 45.40 美元增加了 3.08%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770832830_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="價格目標圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770832830_0.png"/></p>
<h2>解讀分析師評級：深入分析</h2>
<p>通過對最近分析師行動的全面分析，描繪出 Harmony Biosciences Hldgs 在金融專家中的認知。以下總結了關鍵分析師、他們最近的評估以及對評級和價格目標的調整。</p>
<table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>上調</td>
<td>中立</td>
<td>$46.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Truist Securities</td>
<td>下調</td>
<td>買入</td>
<td>$45.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>上調</td>
<td>超越大盤</td>
<td>$46.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Patrick R. Trucchio</td>
<td>HC Wainwright  Co.</td>
<td>維持</td>
<td>買入</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>維持</td>
<td>買入</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>關鍵見解：</h3>
<ul>
<li><strong>採取的行動：</strong> 分析師根據市場條件和公司表現調整他們的建議。無論是 “維持”、“上調” 還是 “下調”，都反映了他們對 Harmony Biosciences Hldgs 近期發展的反應。這些信息提供了分析師對公司當前狀態的看法快照。</li>
<li><strong>評級：</strong> 深入評估，分析師賦予定性值，從 “超越大盤” 到 “跑輸大盤”。這些評級傳達了對 Harmony Biosciences Hldgs 相對於更廣泛市場表現的預期。</li>
<li><strong>價格目標：</strong> 深入分析，分析師提供對 Harmony Biosciences Hldgs 股票未來價值的估計。這一分析揭示了分析師預期隨時間的變化。</li>
</ul>
<p>為了全面瞭解 Harmony Biosciences Hldgs 的市場表現，請將這些分析師評估與重要財務指標結合起來。保持信息靈通，利用我們的評級表做出明智的決策。</p>
<p>隨時瞭解 Harmony Biosciences Hldgs 的分析師評級。</p>
<h2>關於 Harmony Biosciences Hldgs 的所有信息</h2>
<p>Harmony Biosciences Holdings Inc 是一家商業階段的製藥公司，專注於為生活在罕見神經疾病中的患者開發和商業化療法，以滿足未滿足的醫療需求。該公司的產品 WAKIX（匹託利桑）是一種具有新穎作用機制的分子，專門設計用於通過結合 H3 受體來增加大腦中的組胺信號，並用於治療成年嗜睡症患者的肌無力發作。其管線中的其他藥物候選者包括匹託利桑、HBS-102（MCHR1 拮抗劑）、BP1.15205（食慾素-2 受體激動劑）、ZYN002（大麻二酚凝膠）、EPX-100（氯米扎氯鹽酸鹽）和 EPX-200（洛卡特普）等。</p>
<h3>關鍵指標：Harmony Biosciences Hldgs 的財務健康狀況</h3>
<p><strong>市值分析：</strong> 該公司的市值低於行業平均水平，表明其相較於同行相對較小。這可能由於多種因素，包括被認為的增長潛力或運營規模。</p>
<p><strong>收入增長：</strong> Harmony Biosciences Hldgs 在 3M 的卓越表現顯而易見。截至 2025 年 9 月 30 日，該公司實現了 <strong>28.71%</strong> 的顯著收入增長率。這標誌着公司頂線收益的顯著增加。與醫療保健行業的其他公司相比，該公司面臨挑戰，增長率低於同行的平均水平。</p>
<p><strong>淨利潤率：</strong> Harmony Biosciences Hldgs 的財務實力體現在其卓越的淨利潤率上，超過行業平均水平。該公司的淨利潤率達到 <strong>21.24%</strong>，展示了強大的盈利能力和有效的成本管理。</p>
<p><strong>股本回報率（ROE）：</strong> Harmony Biosciences Hldgs 的 ROE 超越行業基準，達到 <strong>6.33%</strong>。這表明其財務管理穩健，股東權益資本的使用效率高。</p>
<p><strong>資產回報率（ROA）：</strong> Harmony Biosciences Hldgs 的 ROA 超越行業基準，達到 <strong>4.39%</strong>。這表明其資產管理高效，財務健康狀況良好。</p>
<p><strong>債務管理：</strong> Harmony Biosciences Hldgs 的債務與股本比率低於平均水平，為 <strong>0.2</strong>，採取了謹慎的財務策略，表明其在債務管理方面的平衡方法。</p>
<h2>理解分析師評級的相關性</h2>
<p>銀行和金融系統的專家，分析師專注於特定股票或定義行業的報告。他們的全面研究包括參加公司電話會議和會議，分析財務報表，並與內部人士互動，以生成所謂的股票分析師評級。通常，分析師每季度評估和評級每隻股票一次。</p>
<p>一些分析師還提供有助於決策的指標預測，如收益、收入和增長預期，以進一步指導如何處理某些股票代碼。需要記住的是，儘管股票和行業分析師是專家，但他們也是人類，只能將自己的信念預測給交易者。</p>
<p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>

HRMY

<p>在最新的季度中，分析師對 Harmony Biosciences Hldgs（NASDAQ:HRMY）給出了不同的評級。12 個月的平均目標價為 46.8 美元，比 45.40 美元上漲了 3.08%。主要分析師進行了各種調整：瑞銀將評級上調至中性（46.00 美元），Truist 將評級下調至買入（45.00 美元），瑞穗將評級上調至跑贏大盤（46.00 美元），其他分析師則維持其評級。Harmony 的市值低於行業平均水平，但其報告的收入增長為 28.71%，淨利潤率為 21.24%。該公司專注於罕見神經疾病的治療，財務狀況穩健，債務管理謹慎</p>

<p>In the latest quarter, 5 analysts provided ratings for Harmony Biosciences Hldgs (NASDAQ: HRMY), showcasing a mix of bullish and bearish perspectives.</p>
<div class="lb-trans"><p>在最新的季度中，5 位分析師對 Harmony Biosciences Hldgs（納斯達克：HRMY）提供了評級，展現出看漲和看跌的不同觀點。</p>
</div><p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>以下表格總結了他們最近的評級，提供了過去 30 天情緒變化的概覽，並與前幾個月進行了比較。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $46.8, a high estimate of $55.00, and a low estimate of $42.00. This current average has increased by 3.08% from the previous average price target of $45.40.</p>
<div class="lb-trans"><p>分析師分析的 12 個月價格目標提供了見解，平均目標為 46.8 美元，最高預估為 55.00 美元，最低預估為 42.00 美元。當前平均目標較之前的 45.40 美元增加了 3.08%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770832830_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1770832830_0.png"/></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<div class="lb-trans"><h2>解讀分析師評級：深入分析</h2>
</div><p>A clear picture of Harmony Biosciences Hldgs's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通過對最近分析師行動的全面分析，描繪出 Harmony Biosciences Hldgs 在金融專家中的認知。以下總結了關鍵分析師、他們最近的評估以及對評級和價格目標的調整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$46.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Patrick R. Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>上調</td>
<td>中立</td>
<td>$46.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Truist Securities</td>
<td>下調</td>
<td>買入</td>
<td>$45.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>上調</td>
<td>超越大盤</td>
<td>$46.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Patrick R. Trucchio</td>
<td>HC Wainwright  Co.</td>
<td>維持</td>
<td>買入</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>維持</td>
<td>買入</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>關鍵見解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Harmony Biosciences Hldgs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Harmony Biosciences Hldgs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Harmony Biosciences Hldgs's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>採取的行動：</strong> 分析師根據市場條件和公司表現調整他們的建議。無論是 “維持”、“上調” 還是 “下調”，都反映了他們對 Harmony Biosciences Hldgs 近期發展的反應。這些信息提供了分析師對公司當前狀態的看法快照。</li>
<li><strong>評級：</strong> 深入評估，分析師賦予定性值，從 “超越大盤” 到 “跑輸大盤”。這些評級傳達了對 Harmony Biosciences Hldgs 相對於更廣泛市場表現的預期。</li>
<li><strong>價格目標：</strong> 深入分析，分析師提供對 Harmony Biosciences Hldgs 股票未來價值的估計。這一分析揭示了分析師預期隨時間的變化。</li>
</ul>
</div><p>To gain a panoramic view of Harmony Biosciences Hldgs's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<div class="lb-trans"><p>為了全面瞭解 Harmony Biosciences Hldgs 的市場表現，請將這些分析師評估與重要財務指標結合起來。保持信息靈通，利用我們的評級表做出明智的決策。</p>
</div><p>Stay up to date on Harmony Biosciences Hldgs analyst ratings.</p>
<div class="lb-trans"><p>隨時瞭解 Harmony Biosciences Hldgs 的分析師評級。</p>
</div><h2>All You Need to Know About Harmony Biosciences Hldgs</h2>
<div class="lb-trans"><h2>關於 Harmony Biosciences Hldgs 的所有信息</h2>
</div><p>Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.</p>
<div class="lb-trans"><p>Harmony Biosciences Holdings Inc 是一家商業階段的製藥公司，專注於為生活在罕見神經疾病中的患者開發和商業化療法，以滿足未滿足的醫療需求。該公司的產品 WAKIX（匹託利桑）是一種具有新穎作用機制的分子，專門設計用於通過結合 H3 受體來增加大腦中的組胺信號，並用於治療成年嗜睡症患者的肌無力發作。其管線中的其他藥物候選者包括匹託利桑、HBS-102（MCHR1 拮抗劑）、BP1.15205（食慾素-2 受體激動劑）、ZYN002（大麻二酚凝膠）、EPX-100（氯米扎氯鹽酸鹽）和 EPX-200（洛卡特普）等。</p>
</div><h3>Key Indicators: Harmony Biosciences Hldgs's Financial Health</h3>
<div class="lb-trans"><h3>關鍵指標：Harmony Biosciences Hldgs 的財務健康狀況</h3>
</div><p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 該公司的市值低於行業平均水平，表明其相較於同行相對較小。這可能由於多種因素，包括被認為的增長潛力或運營規模。</p>
</div><p><strong>Revenue Growth:</strong> Harmony Biosciences Hldgs's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of <strong>28.71%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<div class="lb-trans"><p><strong>收入增長：</strong> Harmony Biosciences Hldgs 在 3M 的卓越表現顯而易見。截至 2025 年 9 月 30 日，該公司實現了 <strong>28.71%</strong> 的顯著收入增長率。這標誌着公司頂線收益的顯著增加。與醫療保健行業的其他公司相比，該公司面臨挑戰，增長率低於同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Harmony Biosciences Hldgs's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>21.24%,</strong> the company showcases strong profitability and effective cost management.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> Harmony Biosciences Hldgs 的財務實力體現在其卓越的淨利潤率上，超過行業平均水平。該公司的淨利潤率達到 <strong>21.24%</strong>，展示了強大的盈利能力和有效的成本管理。</p>
</div><p><strong>Return on Equity (ROE):</strong> Harmony Biosciences Hldgs's ROE excels beyond industry benchmarks, reaching <strong>6.33%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> Harmony Biosciences Hldgs 的 ROE 超越行業基準，達到 <strong>6.33%</strong>。這表明其財務管理穩健，股東權益資本的使用效率高。</p>
</div><p><strong>Return on Assets (ROA):</strong> Harmony Biosciences Hldgs's ROA excels beyond industry benchmarks, reaching <strong>4.39%</strong>. This signifies efficient management of assets and strong financial health.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> Harmony Biosciences Hldgs 的 ROA 超越行業基準，達到 <strong>4.39%</strong>。這表明其資產管理高效，財務健康狀況良好。</p>
</div><p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.2</strong>, Harmony Biosciences Hldgs adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> Harmony Biosciences Hldgs 的債務與股本比率低於平均水平，為 <strong>0.2</strong>，採取了謹慎的財務策略，表明其在債務管理方面的平衡方法。</p>
</div><h2>Understanding the Relevance of Analyst Ratings</h2>
<div class="lb-trans"><h2>理解分析師評級的相關性</h2>
</div><p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<div class="lb-trans"><p>銀行和金融系統的專家，分析師專注於特定股票或定義行業的報告。他們的全面研究包括參加公司電話會議和會議，分析財務報表，並與內部人士互動，以生成所謂的股票分析師評級。通常，分析師每季度評估和評級每隻股票一次。</p>
</div><p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<div class="lb-trans"><p>一些分析師還提供有助於決策的指標預測，如收益、收入和增長預期，以進一步指導如何處理某些股票代碼。需要記住的是，儘管股票和行業分析師是專家，但他們也是人類，只能將自己的信念預測給交易者。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>
</div>

Harmony Biosciences Hldgs 在分析師眼中的地位如何